TL;DR: AOD-9604 is a 16-amino-acid fragment of human growth hormone designed to mimic HGH's fat-burning effect without HGH's growth-stimulating effects. Tirzepatide is a dual GIP/GLP-1 incretin agonist with the strongest standalone weight-loss data of any peptide compound. They occupy completely different mechanism categories — metabolic fat-oxidation enhancer vs appetite/incretin pathway modulator — and produce very different effect sizes.
TL;DR — quick comparison table
| Dimension | AOD-9604 | Tirzepatide |
|---|---|---|
| Mechanism | HGH fragment 177–191 (lipolysis stimulation) | GIP + GLP-1 dual agonist (incretin amplification) |
| Peak weight loss (trial) | ~2.6–3.5% over 12 weeks (Heffernan, 2014) | ~22.5% over 72 weeks (SURMOUNT-1) |
| Trial stage | Phase 2 complete; further development paused | Phase 3 complete |
| Typical reference dose | 300 mcg daily, subcutaneous | 2.5–15 mg weekly |
| Common side effects | Mild injection-site reactions, rare | Nausea, mild GI |
| PH availability | Available, niche | Wide availability |
| Noki Labs price | ₱1,500 (2 mg vial) | ₱2,000–₱3,500 |
| Best for | Lean recomposition, low side-effect tolerance | Significant body-weight reduction |
How each peptide works (the science)
AOD-9604: HGH fragment, fat-oxidation focus
AOD-9604 corresponds to amino acids 177–191 of human growth hormone — the C-terminal fragment that retains HGH's lipolytic activity (stimulating fat oxidation in adipocytes) without HGH's growth-stimulating effects (no IGF-1 elevation, no anabolic signaling). It works by activating beta-adrenergic-like pathways in adipocytes, increasing lipolysis and fat oxidation, particularly during fasting states.
Effect sizes are modest. AOD-9604 is best understood as a recomposition adjunct — a small metabolic nudge — not a primary weight-loss intervention.
Tirzepatide: dual incretin amplification
Tirzepatide simultaneously activates GIP and GLP-1 receptors, amplifying post-meal insulin response, slowing gastric emptying, and dampening hypothalamic appetite drive. The mechanism produces the steepest mono-peptide weight-loss curve of any approved-class compound. The trade-off is the standard incretin GI profile.
Clinical evidence — head to head
AOD-9604: Heffernan et al. (PubMed 2001) characterised AOD-9604's lipolytic mechanism in adipocyte models. The phase-2 obesity trial reported 2.6–3.5% weight loss over 12 weeks at 1 mg daily — statistically significant but modest. Further development was discontinued after these phase-2 efficacy ceilings became clear.
Tirzepatide: SURMOUNT-1 (Jastreboff et al., NEJM 2022) showed 20.9% weight reduction at 15 mg over 72 weeks. SURPASS-2 demonstrated superiority over semaglutide head-to-head.
Effect sizes are not comparable. Tirzepatide produces ~6x the weight loss in matched-duration analyses. AOD-9604 is fundamentally a different category of intervention.
Cost in the Philippines
| Protocol | Vials | Total cost |
|---|---|---|
| AOD-9604, 12-week daily protocol | ~6 vials (2 mg each) | ~₱9,000 |
| Tirzepatide, 12-week titrated protocol | ~3 vials (10 mg each) | ~₱8,400 |
Tirzepatide is essentially the same cost per cycle for ~6x the effect on body weight — if weight loss is the goal. AOD-9604 is competitive only for recomposition or fat-oxidation use cases. Apply WELCOME10 for 10% off first order.
Side effects — what's different
AOD-9604 is among the most well-tolerated injectable peptides — occasional mild injection-site redness, rare GI complaints. No incretin-class nausea, no growth-related effects, no glycaemic disturbance. Tirzepatide carries the standard incretin GI signature: nausea (peak weeks 2–6 after each titration step), occasional vomiting, mild constipation. Both are manageable when run per-protocol.
Which is better for [persona/goal]?
If you want significant weight loss
Tirzepatide. Not even close. Use AOD-9604 only for recomposition or specific fat-oxidation goals.
If you want minimal side effects
AOD-9604. Significantly cleaner profile.
If you want lean-mass-protective fat loss
AOD-9604, often stacked with growth-axis or recovery peptides like MOTS-c for cellular metabolic support.
If you're already running Tirzepatide
AOD-9604 can be layered without pharmacological conflict, particularly to maintain fat-oxidation drive during late-stage protocols where energy expenditure naturally drops.
Combining them
The two are mechanistically non-overlapping, so co-administration is pharmacologically rational. Some clinical protocols pair AOD-9604 daily with weekly Tirzepatide to add a fat-oxidation layer to the appetite-suppression base.
Where to buy in the Philippines
- AOD-9604 2 mg: /products/aod-9604 — ₱1,500
- Tirzepatide: /products/tirzepatide — ₱2,000–₱3,500, 4 variants
Browse the weight-management collection. Pillar detail at /pages/aod-9604-philippines and /pages/tirzepatide-philippines. Compare AOD against another HGH-axis peptide at /pages/mots-c-vs-aod-9604. Manila customers, /pages/peptide-supplier-manila.
FAQ
Q: Is AOD-9604 a GLP-1? No. It's an HGH fragment with lipolytic activity.
Q: Will AOD-9604 raise my IGF-1? No — the fragment was specifically designed without HGH's growth-axis effects.
Q: Why is Tirzepatide so much more effective for weight loss? Different mechanism: appetite suppression and incretin-mediated metabolic shift, vs AOD's modest fat-oxidation nudge.
Q: Can I use AOD-9604 daily long-term? Most clinical protocols cycle 12–16 weeks on, with a comparable break.
Q: Which is safer? Both have favourable safety records. AOD-9604 is gentler on GI; Tirzepatide has more long-term human data.
Always consult a licensed healthcare provider before starting any new peptide or wellness regimen. Individual results vary. Statements about our products are educational and not intended to diagnose, treat, cure, or prevent any disease.
Last reviewed: May 2026 · Read more in our FAQ